阐明神经丝在阻塞性睡眠呼吸暂停的认知衰退中的参与及其可能作为生物标志物的作用
Julia Jaromirska1, Piotr Kaczmarski1, Dominik Strzelecki2
1Department of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, Lodz, Poland.
Frontiers in psychiatry
|December 15, 2023
概括
阻塞性睡眠呼吸暂停 (OSA) 与认知能力下降和神经退行有关. 神经纤维素作为OSA患者这些变化的非侵入性生物标志物具有前景.
科学领域:
- 神经科学是一个神经科学.
- 睡眠医学 睡眠医学
- 生物标志物研究 生物标志物研究
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 是一种普遍存在的睡眠障碍,与显著的神经精神疾病并发症有关,包括认知障碍.
- 慢性间歇性缺氧和OSA中的睡眠碎片化会导致神经元损伤,导致神经退行以及阿尔茨海默病等疾病.
- 将OSA与认知缺陷联系在一起的精确机制,例如神经退行与抑郁症,是复杂的,需要先进的诊断.
研究的目的:
- 审查目前关于神经纤维素在OSA患者认知衰退和神经退行症中的作用的知识.
- 探索神经纤维作为评估OSA中大脑变化的非侵入性生物标志物的潜力.
- 讨论神经纤维在OSA认知障碍途径区分中的实用性.
主要方法:
- 关于阻塞性睡眠呼吸暂停,认知障碍,神经退行和生物标志物研究的文献综述.
- 分析研究研究神经纤维 (例如神经纤维光链) 作为神经元损伤的指标的研究.
- 对在OSA群体中关联神经纤维水平与认知功能的研究进行检查.
主要成果:
- 神经纤维素作为神经元特异性细胞骨蛋白质,与在各种神经疾病中观察到的神经退行有关.
- 在阻塞性睡眠呼吸暂停患者中,神经纤维水平升高可能表明神经元损伤和认知缺陷.
- 神经纤维素也显示出在其他睡眠障碍 (如失眠) 中作为生物标志物的潜力.
结论:
- 神经丝是一种有希望的,非侵入性的生物标志物,用于检测与阻塞性睡眠呼吸暂停相关的神经退行和认知衰退.
- 对神经纤维的进一步研究可能有助于理解和管理OSA的神经精神疾病并发症.
- 通过利用神经丝生物标志物,可以增强OSA认知障碍的差异化病理机制.
更多相关视频
相关概念视频
Sleep-Wake Cycles
1.4K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.4K
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492


